Office Number: 203-815-5782
CaroGen Expands its Board of Directors and Development Leadership Team
Farmington, CT - April 17, 2017: CaroGen today announced an important addition to its Board of Directors (Dr. Jo Viney) and two key senior executive level scientists (Dr. Steven Mason and Dr. Timur Yarovinsky) to its immunotherapy discovery and development team. Click here to read the full press release
CaroGen and University of Connecticut Colon Cancer Immunotherapy Collaboration Highlighted in Colon Cancer News Today
Farmington, CT - January 26, 2017: CaroGen and researchers at the University of Connecticut have initiated a collaboration on development of a colon cancer immunotherapy. This collaboration was highlighted in Colon Cancer News Today. Click here to read the full article.
UCONN Health Researchers Collaborate with CaroGen Corporation to Develop Vaccine to Treat Colon Cancer
Farmington, CT - November 8, 2016: The University of Connecticut and CaroGen Corporation, an emerging immunotherapy company, today announced a collaboration aimed at developing a therapeutic vaccine for treatment of patients with colon cancer. CaroGen’s proprietary technology platform will be applied to a specific target studied by UConn Health’s Dr. Kepeng Wang Ph.D., Assistant Professor of Immunology. Click here to read the full press release
CaroGen Forms Zika Vaccine Consortium
Farmington, CT - November 7, 2016: CaroGen Corporation, announced today that it has formed a consortium comprising CaroGen, the University of Connecticut and Yale University School of Medicine scientists to accelerate the development of a Zika virus vaccine. Click here to read the full press release.
CaroGen Raiess $1M in Series A Funds
Farmington, CT - October 19, 2016: CaroGen Corporation announced today that it has raised $1 million dollars through GP Fortune Investment Partners (GPFI), LLC, to advance the company's Heptatis B Virus (HBV) immunotherapy. Click here to read the full press release.
CaroGen in the News:
August 8, 2016: CaroGen’s CEO Bijan Almassian was profiled by the Hartford Business Journal where he discusses CaroGen's technology, products to treat or prevent Hepatitis B, Zika and C. difficile infections and financing. Click here to read the full interview.
July 5, 2016: Connecticut Senators Murphy and Blumenthal pushing for Zika virus response funding. Click here for the story.
SPARK Commercialization Grant Award for C. difficile Vaccine
Farmington, CT - April 18, 2016: CaroGen announced today that University of Connecticut collaborator, Dr. Kamal Khanna, was awarded a SPARK Commercialization Fund grant from the University of Connecticut. The grant is to support the research and development of a VLV-based vaccine against C. difficile infection. The award will support the creation of candidate VLV vaccines and testing their immunogenicity in preclinical models. Click here to read the award notification from SPARK.
CT Backs CaroGen’s Quest to Fight Cancer, Hepatitis B
March 7, 2016: An interview with CaroGen’s President and CEO was published in the Hartford Business Journal where he provides an update on CaroGen’s product development: Click here to read the full interview.
CaroGen Announces Publication of HBV Vaccine Preclinical Research
Hamden CT - August 17, 2015 - CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.
CaroGen Fostering Vaccine Development Collaborations with Yale & UConn and Establishing Laboratory
Farmington CT – January 5, 2015 – CaroGen Corporation today announced that it has chosen UConn’s Technology Incubation Program (TIP) in Farmington to establish a laboratory footprint. This expansion will allow CaroGen to more aggressively pursue the advancement of its proprietary virus-like vesicle (VLV) vaccine technology, development of its HBV vaccine program and evaluation of other potential candidate infectious disease vaccines.
CaroGen Receives $500,000 Investment from Connecticut Bioscience Innovation Fund (CBIF)
Hamden CT – December 10, 2014 – CaroGen has been awarded $500,000 from the CBIF to support the continued development of CaroGen's therapeutic Hepatitis B Virus (HBV) vaccine.
CaroGen Wins Entrepreneur Innovation Award from CTNext
Hamden CT – April 3, 2014 – CaroGen was awarded a $10,000 grant by CTNext, a component of Connecticut’s innovation ecosystem to support the success of companies and entrepreneurs, to further support development of its therapeutic vaccine for chronic Hepatitis B (CHB) viral infection.
Every employee at CaroGen Corporation has the opportunity to develop their career, contribute to our success, and make a positive impact on national and international health initiatives. We offer an intellectually challenging, rewarding, and high-energy work environment, and we recognize that our employees are fundamental to achieving our goals and meeting the needs of the clinical and public health communities.
To apply for any of our open positions, please send your resume to:
Please include the position that you are applying for in the subject line.
EQUAL EMPLOYMENT OPPORTUNITY STATEMENT
CaroGen Corporation provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. CaroGen Corporation complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.
CaroGen Corporation expressly prohibits any form of unlawful employee harassment based on race, color, religion, gender, sexual orientation, national origin, age, genetic information, disability, or veteran status. Improper interference with the ability of CaroGen Corporation’s employees to perform their expected job duties is absolutely not tolerated